Pluristem Therapeutics Inc. (PSTI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluristem Therapeutics Inc. on January 3, 2022, reporting an event that occurred on January 1, 2022. The company is incorporated in Nevada and maintains its principal executive offices in Haifa, Israel. It trades on The Nasdaq Global Market under the symbol PSTI.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate governance event rather than financial performance data.
Material Changes
On January 1, 2022, the Company, through its subsidiary, entered into a Consulting Agreement with Mr. Zami Aberman. Under this agreement, Mr. Aberman serves as the Company's Chairman of the Board of Directors. A copy of the agreement is filed as Exhibit 10.1.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the appointment of the Chairman.
Key Facts for Investor Verification
- Confirmation of Mr. Zami Aberman's appointment as Chairman of the Board effective January 1, 2022.
- Review of the specific terms and compensation details within the Consulting Agreement filed as Exhibit 10.1.
- Verification of any potential conflicts of interest associated with the new Chairman.